This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Innovate UK grant to further development of OrthoSon ultrasound technology in back pain

Innovate UK grant to further development of OrthoSon ultrasound technology in back pain

29 Jul 2020

Innovate UK grant to further development of ultrasound technology in back pain Data from extended Biomedical Catalyst award to support progression of OrthoSon technology towards first-in-human trial Oxford, UK, July 29 2020 – OrthoSon, an Oxford University spin-out which is developing a novel ultrasound-based treatment for lower back and neck pain, has been awarded a £250,000 extension to its £1.2m Biomedical Catalyst award. The extension,... Read more

Practical completion achieved for Bellhouse Building

Practical completion achieved for Bellhouse Building

06 Jul 2020

Practical completion achieved for Bellhouse Building First tenants to move in to TOSP’s newest building by end of summer Oxford, UK, July 6 2020 – The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, is pleased to announce that its newest facility, the 30,000 sq ft Bellhouse Building, has reached practical completion. The first occupiers are expected to move in by the end of the summer, and there... Read more

OxSonics Therapeutics Raises £10.5m in Oversubscribed Series B2 Equity Financing

OxSonics Therapeutics Raises £10.5m in Oversubscribed Series B2 Equity Financing

01 Jul 2020

Oxford, UK – 1st July 2020 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that a £10.5m Series B2 financing round had been closed. The financing round consisting of existing and new investors was oversubscribed. The capital will be used to take OxSonics’ innovative SonoTran® platform technology into first-in-human clinical... Read more

Immune cell regulation company MiroBio relocates to The Oxford Science Park

Immune cell regulation company MiroBio relocates to The Oxford Science Park

01 Jul 2020

Oxford, UK, 1 July 2020 – The community of innovative companies at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is being enhanced by the addition of MiroBio, a novel therapeutics company based on insights into the regulation of receptor signalling in immune cells. MiroBio, which launched in October last year with a  £27m Series A round, is taking laboratory and office space at the Park as it... Read more

EVOX THERAPEUTICS ANNOUNCES MULTI-TARGET RNA INTERFERENCE & ANTISENSE RESEARCH COLLABORATION/LICENSE AGREEMENT WITH LILLY

EVOX THERAPEUTICS ANNOUNCES MULTI-TARGET RNA INTERFERENCE & ANTISENSE RESEARCH COLLABORATION/LICENSE AGREEMENT WITH LILLY

09 Jun 2020

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox’s proprietary DeliverEXTM platform to develop and deliver RNA interference... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More